公开(公告)号：US20200270348A1

公开(公告)日：2020-08-27

申请号：US16872158

申请日：2020-05-11

Applicant: Ventana Medical Systems, Inc. ,  Spring BioScience Corporation

Inventor： Marcin KOWANETZ ,  Hartmut KOEPPEN ,  Zachary BOYD ,  Zhiming LIAO ,  Yifei ZHU ,  Bharathi VENNAPUSA ,  Patrick C. ROCHE

IPC: C07K16/28 ,  G01N33/53 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  G01N33/574

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

公开(公告)号：US20160009805A1

公开(公告)日：2016-01-14

申请号：US14726329

申请日：2015-05-29

Applicant: GENENTECH, INC. ,  SPRING BIOSCIENCE CORPORATION ,  VENTANA MEDICAL SYSTEMS, INC.

Inventor： Marcin KOWANETZ ,  Hartmut KOEPPEN ,  Zachary BOYD ,  Zhiming LIAO ,  Yifei ZHU ,  Bharathi VENNAPUSA ,  Patrick C. ROCHE

IPC: C07K16/28 ,  G01N33/574 ,  A61K39/395 ,  C07K14/705 ,  A61K45/06

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K45/06 ,  A61N2005/1021 ,  C07K14/70532 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/30 ,  G01N33/53 ,  G01N33/57484 ,  G01N2500/10 ,  G01N2800/52

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract translation: 本发明提供程序性死亡 - 配体1（PD-L1）抗体及其使用方法。

公开(公告)号：US20180022809A1

公开(公告)日：2018-01-25

申请号：US15727388

申请日：2017-10-06

Applicant: Genentech, Inc. ,  Spring BioScience Corporation ,  Ventana Medical Systems, Inc.

Inventor： Marcin KOWANETZ ,  Hartmut KOEPPEN ,  Zachary BOYD ,  Zhiming LIAO ,  Yifei ZHU ,  Bharathi VENNAPUSA ,  Patrick C. ROCHE

IPC: C07K16/28 ,  G01N33/574 ,  A61K39/395 ,  G01N33/53 ,  A61K45/06 ,  C07K14/705 ,  A61N5/10

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

公开(公告)号：US20230159641A1

公开(公告)日：2023-05-25

申请号：US18057465

申请日：2022-11-21

Applicant: Ventana Medical Systems, Inc.

Inventor： Marcin KOWANETZ ,  Hartmut KOEPPEN ,  Zachary BOYD ,  Zhiming LIAO ,  Yifei ZHU ,  Bharathi VENNAPUSA ,  Patrick C. ROCHE

IPC: C07K16/28 ,  G01N33/53 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  G01N33/574

CPC classification number: C07K16/2827 ,  G01N33/53 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/70532 ,  G01N33/57484 ,  A61N2005/1021

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.